Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if BL-8040 in combination with
cytarabine (Ara-C) can help to control the disease in patients with Acute Myeloid Leukemia
(AML) that has relapsed or did not respond adequately to previous treatment. The safety of
the study drug combination will also be studied.